NCT07087314View on ClinicalTrials.gov

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

July 9, 2028

Study Completion Date

July 9, 2029

Conditions
Nephrotic Syndrome in Children
Interventions
DRUG

SG301 Subcutaneous injection

Subcutaneous injection every weeks (QW\*6),subsequently, administer it once every two weeks for a total of three times (Q2W\*3). The total number of doses is nine.

Trial Locations (3)

310052

RECRUITING

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

430030

NOT_YET_RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan

450018

NOT_YET_RECRUITING

Henan Children's Hospital Zhengzhou Children's Hospital, Zhengzhou

All Listed Sponsors
lead

Mao Jianhua

OTHER

NCT07087314 - A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence | Biotech Hunter | Biotech Hunter